SCHEMBL31443512

SCHEMBL31443512

C[C@H](/C=C/S(C)(=O)=O)NC(=O)c1ccc(N2CCCOCC2c2ccccc2Cl)cc1F

nearest known ligand 0.34

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 2/20 0.34
MAPK1 P28482 1/20 0.33
NR1H2 P55055 3/20 0.32
NR1H3 Q13133 2/20 0.32
PDE4A P27815 1/20 0.32
PDE4B Q07343 1/20 0.32
PDE4C Q08493 1/20 0.32
PDE4D Q08499 1/20 0.32
DHODH Q02127 2/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
MMP2 P08253 1/20 0.31
MMP13 P45452 1/20 0.31
NR1H4 Q96RI1 3/20 0.31
KCNK3 O14649 1/20 0.31
MAPT P10636 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31443607 1.00 SCN9A (0.34) SCN9AMAPK1NR1H2NR1H3PDE4A
SCHEMBL31443496 0.95 MAPK1 (0.36) SCN9AMAPK1NR1H2NR1H3DHODH
SCHEMBL31443518 0.95 MAPK1 (0.36) SCN9AMAPK1NR1H2NR1H3DHODH
SCHEMBL31443697 0.90 SCN9A (0.41) SCN9ANR1H2NR1H3
SCHEMBL31443523 0.89 SCN9A (0.39) SCN9AMAPK1NR1H2NR1H3
SCHEMBL31443472 0.89 SCN9A (0.39) SCN9AMAPK1NR1H2NR1H3
SCHEMBL31444591 0.89 MEN1 (0.35) SCN9AMAPK1NR1H2NR1H3MEN1
SCHEMBL31443473 0.89 MEN1 (0.35) SCN9AMAPK1NR1H2NR1H3MEN1
SCHEMBL31443784 0.88 MAPK1 (0.38) MAPK1KCNK3
SCHEMBL31443805 0.88 MAPK1 (0.35) MAPK1MEN1KMT2ANR1H4MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025072451-A1 RAS-PI3K INHIBITORS FOR THE TREATMENT OF CANCER AND IMMUNOLOGICAL DISEASES VIVIDION THERAPEUTICS, INC. (US) 2025-04-03 WO claimed
WO-2025072451-A1 RAS-PI3K INHIBITORS FOR THE TREATMENT OF CANCER AND IMMUNOLOGICAL DISEASES VIVIDION THERAPEUTICS, INC. (US) 2025-04-03 WO disclosed